Inspire Medical Systems, Inc. $INSP Shares Sold by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. has reduced its stake in Inspire Medical Systems by 41.2%, now holding 47,642 shares valued at approximately $7.59 million.
• Institutional investors collectively own 94.91% of Inspire Medical Systems, with significant increases in stakes from firms like Northern Trust Corp and Algert Global LLC noted.
• Inspire Medical Systems announced a $200 million share repurchase plan, indicating that the company's board finds its shares to be undervalued.

Capital Fund Management S.A. lowered its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 41.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,642 shares of the company's stock after selling 33,342 shares during the period. Capital Fund Management S.A. owned 0.16% of Inspire Medical Systems worth $7,588,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INSP. Northern Trust Corp lifted its stake in shares of Inspire Medical Systems by 6.6% in the 1st quarter. Northern Trust Corp now owns 260,407 shares of the company's stock valued at $41,478,000 after purchasing an additional 16,158 shares during the last quarter. Algert Global LLC lifted its stake in shares of Inspire Medical Systems by 39.1% in the 1st quarter. Algert Global LLC now owns 59,820 shares of the company's stock valued at $9,528,000 after purchasing an additional 16,808 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Inspire Medical Systems by 64.4% in the 1st quarter. American Century Companies Inc. now owns 18,432 shares of the company's stock valued at $2,936,000 after purchasing an additional 7,218 shares during the last quarter. Oak Ridge Investments LLC lifted its stake in shares of Inspire Medical Systems by 4.8% in the 1st quarter. Oak Ridge Investments LLC now owns 26,090 shares of the company's stock valued at $4,156,000 after purchasing an additional 1,186 shares during the last quarter. Finally, Fox Hill Wealth Management acquired a new position in shares of Inspire Medical Systems in the 1st quarter valued at $752,000. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Trading Down 1.4%

INSP opened at $91.7640 on Friday. The stock's 50-day moving average price is $118.18 and its 200 day moving average price is $145.50. Inspire Medical Systems, Inc. has a 12-month low of $73.92 and a 12-month high of $225.00. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of 53.04, a PEG ratio of 2.90 and a beta of 1.22.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The firm had revenue of $217.09 million for the quarter, compared to analyst estimates of $214.50 million. During the same quarter in the prior year, the company earned $0.32 EPS. Inspire Medical Systems's revenue was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its board has initiated a share repurchase plan on Monday, August 11th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 8.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. KeyCorp lowered Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a research note on Tuesday, August 5th. Wall Street Zen lowered Inspire Medical Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Stifel Nicolaus set a $140.00 price target on Inspire Medical Systems and gave the company a "hold" rating in a research note on Tuesday, August 5th. Royal Bank Of Canada decreased their price target on Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 5th. Finally, JPMorgan Chase & Co. lowered Inspire Medical Systems from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $195.00 to $110.00 in a research note on Tuesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $165.62.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.